Introduction
Lung cancer is a major health concern worldwide -with an estimated 1.8 million new cases globally in 2012, representing 12.9% of all new cancer cases [1, 2] . New immunotherapeutic treatments for lung cancer that exploit or protect immune surveillance have shown great promise. The immune system can recognize and destroy tumors, but can be prevented from doing so by programmed death ligand-1 (PD-L1) that is expressed on tumor cells. PD-L1 binds to programmed death-1 (PD-1) on cytotoxic T cells to inhibit their activity and up to 68% of non-small-cell lung cancer (NSCLC) cases reportedly express PD-L1 [3] [4] [5] [6] . In 2014, the Food and Drug Administration approved pembrolizumab, a therapeutic antibody that blocks lymphocytic PD-1, for the treatment of advanced NSCLC. However, there is currently no standard treatment for double cancer (which is usually diagnosed in older individuals) as it is difficult to carry out a large-scale study. As various treatment modalities are being developed, the prognosis of many severe cancers (including lung cancer) is improving and Food and Drug Administration approval (May 2017) of pembrolizumab as a first-line treatment for any solid tumor with certain genetic features has contributed to this improvement.
Here, we report two cases of double cancer involving NSCLC in which pembrolizumab was effective for the treatment of both cancers. In case 1, during lung cancer treatment, symptoms related to another solid tumor progressed. In case 2, during gastric cancer treatment, symptoms because of lung cancer progression were observed.
Case presentation Case 1
An 83-year-old man presented with an abnormal opacity on chest radiography during a health check. He had a 63 packyear history of smoking and a history of cerebellar infarction, diabetes, and lumbar disc herniation. No obvious family history for cancer was found. Chest computed tomography showed a 33-mm mass at the S3 region of the left lung and the subaortic lymph node was swollen (24 mm). Bronchoscopic lung biopsy was performed and he was diagnosed with stage IIIA squamous cell carcinoma (cT2aN2M0). Because evidence for chemoradiotherapy is poor for individuals older than 80 years of age, chemotherapy alone was performed with four cycles of carboplatin in addition to paclitaxel. Evaluation at the end of the fourth course showed that the disease remained progressive, but the patient and his family requested a secondline treatment other than cytotoxic anticancer drugs. PD-1 inhibitors have shown durable clinical responses in patients with lung squamous cell carcinoma; therefore, nivolumab, Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.anti-cancerdrugs.com.
the only immune checkpoint inhibitor available in Japan at that time, was adopted as a second-line treatment. By the end of the second course of nivolumab treatment, rapid shrinkage of the lung tumor was observed. At the end of the fifth course of nivolumab, however, the patient was hospitalized for general malaise and an increase in inflammatory response. After hospitalization, no evidence of regrowth of the lung tumor was found, but the patient showed hematuria. Whole-body computed tomographic examination found a protruding tumor in the bladder -a finding consistent with the presence of bladder cancer. Urothelial carcinoma was diagnosed with cytology. As the examined lung tissue was 70% positive for PD-L1 expression, pembrolizumab was selected as a third-line therapy. Interestingly, there is also evidence suggesting that pembrolizumab may be effective for urological cancer [7] . After pembrolizumab treatment, the macroscopic hematuria was almost fully resolved. The patient is currently receiving a 13th course of pembrolizumab without major side effects. The lung tumor has not increased in size and bladder cancer progression has not been observed (Figs 1 and 2 ).
Case 2
A 78-year-old man with a history of diabetes and hypertension who had received oxaliplatin in addition to S-1 treatment for stage IV gastric cancer was examined in our hospital. During the course of chemotherapy for gastric cancer, a small nodule (5 mm) at the S3 region of the left lung was found on chest computed tomography.
Although the gastric cancer and the intraperitoneal lymph node showed good response to the chemotherapy, the lung tumor gradually increased to 31 × 25 mm in size, with enlargement of a mediastinal lymph node and a right adrenal gland tumor. The lung tumor was diagnosed as stage IVB (cT4N2M1b) squamous cell carcinoma. Obstruction in the left main lung bronchus occurred because of the increasing size of the left lung tumor and the patient's general condition showed deterioration (ECOG status 2). While waiting for the results of PD-L1 expression testing, chemotherapy with carboplatin in addition to nab-paclitaxel (adjusted for lung and gastric cancer) was administered. However, on day 6, pneumoniatriggered septic shock occurred, for which noradrenaline was administered, making continuation of the chemotherapy difficult. As the PD-L1 expression of the examined lung cancer tissue was 90% positive after 2 weeks, pembrolizumab was administered as a second-line treatment. The lung tumor shrank rapidly thereafter and the gastric cancer also resolved without recurrence (verified by endoscopic examination) (Figs 3 and 4 ). There were no major side effects and the patient is currently receiving a fourth pembrolizumab course. A detailed treatment for both cases can be found in Supplemental File (Supplemental digital content 1, http://links.lww.com/ACD/A266).
Both patients provided written informed consent, and the local institutional review boards approved the study protocols. 
Discussion
We have introduced two cases of double cancer that showed good response to pembrolizumab. In the first case, the lung cancer was treated successfully with another immune checkpoint inhibitor, but the comorbid bladder cancer progressed, and the patient's general condition worsened. In the second case, the treatment of the gastric cancer was efficacious with another cytotoxic agent, but the lung cancer progressed, and the patient's general condition worsened. The findings of these two cases might appear contradictory, but in such cases of double cancer in elderly individuals, the initially diagnosed cancer is more likely than the second cancer to be treated effectively. Although lung cancer treatment is developing rapidly, the increasing complexity of multiple metastases, genetic components, and comorbidities confound standardization of therapy. To this end, it has been proposed that treatments be classified on the basis of the presence or absence of brain metastasis as the blood-brain barrier as well as genetic mutations could be important complicating factors [8] .
The KEYNOTE-010 Study (NCT01905657) was a randomized, open-label, phase II and III clinical trial comparing the safety and efficacy of pembrolizumab with that of docetaxel in patients with PD-L1-expressing NSCLC tumors [9] . Pembrolizumab showed an improved overall survival benefit at both the tested doses in the total population compared with docetaxel. Pembrolizumab also had a better safety profile than docetaxel, with fewer high-grade adverse effects [9] . Many studies have reported the efficacy of pembrolizumab in bladder cancer and, recently, its economic effects have also been reported [10] [11] [12] . In addition, as with other immune checkpoint inhibitors such as nivolumab, the efficacy of pembrolizumab even for gastric cancer cases was reported in the KEYNOTE-059 study [13] . Compared with relatively rare cancers such as malignant melanoma, the simultaneous occurrence of secondary cancer is more frequently observed with lung cancer because of the larger number of patients. Pulmonologists will have to treat increasing number of patients diagnosed with multiple cancers. In the past, for patients with lung cancer who developed other uncontrolled cancers, palliative care was the only option when the lung cancer did not respond to general anticancer drugs. However, as it is now possible to use immune checkpoint inhibitors, which have few side effects and are indicated for many solid tumors, more patients with double cancer can be treated successfully as in the cases presented here. Recently, attempts have been made to combine several target molecules for treatment [14, 15] . Lung cancer itself is a heterozygous disorder and has been considered difficult to control even when targeting a single molecule. However, there is a possibility that such multicarrier-targeted anticancer drugs combined with checkpoint inhibitors will enable the more effective treatment of multiple cancers. In the literature, it seems as if immunity checkpoint inhibitors are only compared with cytotoxic anticancer drugs, but even in multiple cancers, we can firmly diagnose the molecular features of cancer by biopsy. This leads to the idea that using dual (or multi)-targeted proteins on the basis of individualized molecular features might be more effective than blanket antibody or cytotoxic treatments and this possibility remains to be fully investigated.
Pembrolizumab requires a pathological assessment by biopsy of the lung tumor or its metastatic lesion, these cases have primarily come to the respiratory medicine departments of hospitals. However, immune checkpoint inhibitors may be used more often for the treatment of multiple cancers in many clinical departments as knowledge of their indication increases.
Conclusion
With the rapidly aging global population, diagnoses of double cancer cases are increasing and palliative care was, until recently, the only option for many of these patients. However, as shown in the two cases presented here, innovative new treatments for solid tumors (with immune checkpoint inhibitors such as pembrolizumab) have opened further avenues to treat lung cancer more effectively, even when it is comorbid with other cancers.
